Research
1. Carlson DA, Young KL, Fischer SJ, Ulrich H. An evaluation of the stability and plasma pharmacokinetics of R-lipoic acid (RLA) and R-dihydrolipoic acid (RDHLA) dosage forms in human plasma from healthy volunteers. In: Packer L, Patel M, eds. Alpha Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects. Boca Raton, London, New York: Taylor & Francis Publishers(2008) 235-270. 2. Carlson DA, Smith AR, Fischer SJ, Young KL, Packer L. The Plasma Pharmacokinetics of R-(+)-Lipoic Acid Administered as Sodium R-(+)-Lipoate to Healthy Human Subjects. Altern Med Review (2007) Dec;(4):343-351. 3. Papanas N', Ziegler D. Efficacy of a-lipoic acid in diabetic neuropathy. Expert Opinion Pharmacotherapy (2014) Dec:15(18):2721-31. 4. Maglione E', Marrese C, Migliaro E, Marcuccio F Panico C, Salvati C, Citro G, Quercio M, Roncagliolo E Torello C, Brufani M. Increasing bioavailability of (R)-alpha-lipoic acid to boost antioxidant activity in the treatment of neuropathic pain. Ada Biomed. 2015 Dec 14:86(3):226-33.5. Brufani M', Figliola R. (R)-a-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy. Ada Biomed. 2014 Aug 20;85(2):108-15. 6. M. Ranieri et al, International Journal of Immunopathology and Pharmacology Vol. 22, no. 3, (S) 45-50 (2009). 7. G. di Geronimo, et al. Treatment of carpal tunnel syndrome with alpha-lipoic acid. European Review for Medical and Pharmacological Sciences 2009;13:133-139
1. GLASSMAN E. ORAL IRON THERAPY WITH FERROUS FUMARATE AND POLYSACCHARIDE IRON COMPLEX. ANNA J. 1992;19:277–278, 323. 2. NAUDE S, CLIJSEN S, NAULAERS G, ET AL. IRON SUPPLEMENTATION IN PRETERM INFANTS: A STUDY COMPARING THE EFFECT AND TOLERANCE OF A FE2+ AND A NONIONIC FEIII COMPOUND. J CLIN PHARMACOL. 2000;40:1447–1451. 3. MACDOUGALL IC. MONITORING OF IRON STATUS AND IRON SUPPLEMENTATION IN PATIENTS TREATED WITH ERYTHROPOIETIN. CURR OPIN NEPHROL HYPERTENS. 1994;3:620–625. 4. TINAWI M, MARTIN KJ, BASTANI B. ORAL IRON ABSORPTION TEST IN PATIENTS ON CAPD: COMPARISON OF FERROUS SULFATE AND A POLYSACCHARIDE FERRIC COMPLEX. NEPHRON. 1996;74:291–294. 5. COE EM, BOWEN LH, SPEER JA, BEREMAN RD. COMPARISON OF POLYSACCHARIDE IRON COMPLEXES USED AS IRON SUPPLEMENTS. J INORG BIOCHEM. 1995;57:287–292. 6. SEPIDEH TAGHAVI, AFSANEH AMIRI, AHMAD AMIN. ORAL IRON THERAPY WITH POLYSACCHARIDE-IRON COMPLEX MAY BE USEFUL IN INCREASING THE FERRITIN LEVEL FOR A SHORT TIME IN PATIENTS WITH DILATED CARDIOMYOPATHY. RES CARDIOVASC MED. 2017 JANUARY; 6(1):E39816. 7. WINGARD RL, PARKER RA, ISMAIL N, HAKIM RM. EFFICACY OF ORAL IRON THERAPY IN PATIENTS RECEIVING RECOMBINANT HUMAN ERYTHROPOIETIN. AM J KIDNEY DIS. 1995;25:433–439. 8. SANKLECHA MU. IRON POLYSACCHARIDE COMPLEX. INDIAN PEDIATR. 2002;39:893–894. 9. WANG TP, LIU CR, ZHAO MJ, ET AL. COMPARISON OF THE EFFECT OF A POLYSACCHARIDE IRON COMPLEX (NIFEREX®) AND FERROIDS® ON RENAL DEFICIENCY ANEMIA [IN CHINESE]. PROC CLIN MED J. 2006;15:24–25. 10. MICHAEL ALLEYNE, MD, MCDONALD K. HORNE, MD, AND JEFFERY L. MILLER, MD. INDIVIDUALIZED TREATMENT FOR IRON DEFICIENCY ANEMIA IN ADULTS. AM J MED. AUTHOR MANUSCRIPT; AVAILABLE IN PMC 2009 NOV 1. PUBLISHED IN FINAL EDITED FORM AS: AM J MED. 2008 NOV; 121(11): 943–948. 11. BRITTENHAM G. DISORDERS OF IRON METABOLISM: IRON DEFICIENCY AND OVERLOAD. IN: HOFFMAN R, BENZ EJ JR, SHATTIL SJ, ET AL, EDS. HEMATOLOGY: BASIC PRINCIPLES AND PRACTICE. 3RD ED. NEW YORK, NY: CHURCHILL-LIVINGSTONE; 2000.
1. Liubov Sichel, Diana Zabolotna, Dmytriy Zabolotny. Perspectives of Probiotic Therapy in Sinus Infection, Lytic Enzymes, Academy of Medical Sciences of Ukraine prof. O.S. Kolomychenko Institute of Otolaryngology, 3 Zoologichna str., Kiev, 03680, Ukraine. 2. Tunkel, A. R. and Sepkowitz, K. A. 2002. Infections Caused by Viridans Streptococci in Patients with Neutropenia. Clinical Infectious Diseases 34:1524-9. 3. Melnikov, D. Zabolotnaya. In vitro experimental study of the probiotic effect on the tonsillar cells in the patients with adenoid disease: The journal of ear, nose and throat diseases, 3, 2006, p.24-27. 4. Zabolotny D., Melnilkov., Zabolotnaya D., Shinkarenko L. Probiotic modulation of the immunogenesis in the experiment; Immunology and allergology No1, 2006, p.19-21 5. Vincent J. Iacono, Bruce J. MacKay, Sharon DiRienzo, and Jerry J. Pollock. Selective Antibacterial Properties of Lysozyme for Oral Microorganisms. Infect Immun. 1980 Aug; 29(2): 623–632. 6. Report on clinical use of the probiotic cells Lactobacillus delbrueckii LE and their lysate. A.S. Prylutskyy, MD, PhD, Clinical Immunology and Allergy Department, Donetsk State Medical Univerity, 1000. 7. Savtsova Z.D., Shplevaya S.I., Tarutinov V.I., Rogatskaya V.P., NMeniok T.A., Nikolsky I.S., Mosienko V.S., Shynkarenko L.M., Chekhun V.F. Immune correction by an Immunomodulator from Lactobacillus delbrueckii LE in a combine therapy of breast cancer at stages II and IV. Oncology 2000; 22:211-214. 8. Shplevaya S.I., Tarutinov V.I., Mosienko V.S., Rogatskaya V.P., Ponomarev I.O., Shynkarenko L.M., Chekhun V.F. Correction of leucopenia by a new probiotic immunomodulatory Lactobacillus delbrueckii product in combined treatment of breast cancer. Oncology, 2000;2(1-2):83-86. 9. D. Zabolotny, L. Shynkarenko, O. Melnikov, L. Volosevich, I. Zarytska, O. Goloborodko, G. Karpenko, O. Bolyska, D. Zabolotna. Application of the probiotic medication “Acidolor” in patients with chronic tonsillitis and evaluation of its efficacy; Journal of ear, nose and throat diseases. No5, 2003, pages 2-9. 10. L. Shynkarenko, N. Dehtyrenko. Research of the Chemotherapy drugs influence on Lactic Acid Bacteria cells. Scientifi c news of the NUT “KPI”, 2004, 1(33), pp. 135-140. 11. O. Volska, L. Shynkarenko, I. Zarytska, D. Zabolotna. Study of the possibility of the using of the Lactobacilli for treatment and prevention of the Candida infections in the ENT-organs. Odessa Medical Journal, 2006, 4(96), pp. 32-3. 12. Starovoytova S., Gorchakov V. Lactic Acid Bacteria strain Selection for Effective Probiotics Compositions. 2006, Scientifi c News of NUT “KPI”, v5, pp. 100-103. 13. Starovoytova S. Timoshok N, Gorchakov V, Spivak N. Interferon induction activity of Lactic Acid Bacteria; 2007, Immunology and Allergy (Ukrainian), #4, pp. 24-27. 14. Starovoytova S., Oryabinska L, Gorchakov V. Cholinesterase and protease activity of Lactic Acid Bacteria in vitro; 2007, Environment and Health, #4 (43), pp. 68-71. 15. Starovoytova S, Timoshok, N, Spivak N. Infl uence of Lactic Acid bacteria associated cultures at mice experimental meningoencephalytic herpes infection; 2008, In Abstracts of International Conference “Antibacterial and antiviral therapy on hospital treatment”, Charkob, Ukraine, pp. 316-317. 16. Timoshok N, Shynkarenko L, Staroboytova S, Spivak N. Investigation of interferon induction activity of new Probiotic composition and strains L. Delbrueckii 86, L. rhamnosus to compare with Del-Immune V and Lactoberterin (L. plantarum): 2009, IIX Congress of Ukrainian Microbiological Society, Abstracts Book, p. 264. 17. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Immunomodulating abilities of Lactic Acid Bacteria. 2009; Microbio.J., 71, #3, pp. 41-47. 18. D. Zabolotny, L. Volosevich, I. Zarytska, V.D. Zabolotna. Perspectives of biotherapy in ENT disease; Journal of ear, nose and throat diseases, No3-c, 2003, p. 180-181. 19. O. Volska, D. Zabolotna. Study of the mechanisms of antagonistic activity in different probiotic strains. Journal of ear, nose and throat diseases, No3-c, 2003, p. 164-165. 20. Shynkarenko L., Dehtyrenko N. Adhesion potency of lactic acid bacteria as factor for section of Probiotic strains. Scientifi c News of NUT “KPI”, 2004, 3(35), pp. 102-106. 21. Zabolotny D., Melnilkov O., Zabolotnaya D., Shynkarenko L. Probiotic modulation of immunogenesis in the experiment. Immunology and allergy, 1, 2006., p. 19-21. 22. O. Melnikov, D. Zabolotnaya. Experimental investigation of the Probiotic influence on the palate tonsils cells in patients with chronic tonsillitis in vitro. The journal of ear, nose and throat diseases, 2006, 3. pp. 24-27. 23. Volska, L. Shinkarenko, Zarytska, D. Zabolotna Study of the possibility to use lactic acid bacilli in prevention and treatment of the candidiasis of ENT organs; Odessa medical journal, No4 (96), 2006, 32-36. 24. Melnikov, D Zabolotnaya, L. Kalinovskaya, V. Simonenko. Study of the functional and morphochemical characteristics of cells and tissues under the conditions of the co-cultivation with lactic acid bacilli medication LB3, 2007, 170-172. 25. Timoshok N, Shynkarenko L, Staroboytova S, Spivak N. Investigation of interferon induction activity of new Probiotic composition and strains L. Delbrueckii 86, L. rhamnosus to compare with Del-Immune V and Lactoberterin (L. plantarum): 2009, IIX Congress of Ukrainian Microbiological Society, Abstracts Book, p. 264. 26. Akhremenko YA, Cheremkina AS, Tarasova LA, Ushnitsky ID. MICROBIOCENOSIS IN INFLAMMATORY PROCESSES OF MARGINAL GUM AMONG CHILDREN. Wiad Lek. 2015;68(4):493-5. 27. Zabolotny D., Melnilkov, Zabolotnaya D., Shinkarenko L. Probiotic modulation of the immunogenesis in the experiment; Immunology and allergology No1, 2006, p.19-21
1. Huang SL, Ling PX, Zhang TM: Oral absorption of hyaluronic acid and phospholipid complexes in rats. World J Gastroenterol 2007;13:945–949. 2 Masuko K, Murata M, Yudoh K, Kato T, Nakamura H: Anti-inflamatory effects of hyaluronan in arthritis therapy: not just for viscosity. Int J Gen Med 2009;2:77–81. 3. LUKE R. BUCCI ET AL. WILL THE REAL HYALURONAN PLEASE STAND UP? JOURNAL OF APPLIED NUTRITION, VOLUME 54, NUMBER 1, 2004 REVIEW. 4. Cuixia YangJ et al. -The High and Low Molecular Weight Forms of Hyaluronan Have Distinct Eff ects on CD44 Clustering – J Biol Chem. 2012 Dec 14; 287(51): 43094–43107. 5. Balogh L, Polyak A, Mathe D, Kiraly R, Thuroczy J, Terez M, Janoki G, Ting Y, Bucci L, Schauss A: Absorption, uptake and tissue affinity of high-molecular weight hyaluronan after oral administration in rats and dogs. J Agric Food Chem 2008;56:10582–10593. 6. Yatabe T, Mochizuki S, Takizawa M, Chijiiwa M, Okada A, Kimura T, Fujita Y, Matsumoto H, Toyama Y, Okada Y: Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 2009;68:1051–1058. 7. Tashiro T, Seino S, Sato T, Matsuoka R, Masuda Y, Fukui N. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. Scientific World Journal. 2012;2012:167928. 8. Greco RM, Iocono JA, Ehrlich HP. Hyaluronic acid stimulates human fibroblast proliferation within a collagen matrix. J Cell Physiol. 1998;177(3):465–473. 9. Ricci M, Micheloni GM, Berti M, Perusi F, Sambugaro E, Vecchini E, Magnan B. Clinical comparison of oral administration and visco supplementation of hyaluronic acid (HA) in early knee osteoarthritis. Musculoskelet Surg. 2017;101:45–49. doi: 10.1007/s12306-016-0428-x. 10. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;43(5):593–599. doi: 10.1016/j.semarthrit.2013.10.002. 11. Litwiniuk M., Krejner A., Speyrer M.S., Gauto A.R., Grzela T. Hyaluronic Acid in Infl ammation and Tissue Regeneration. Wounds A Compend. Clin. Res. Pract. 2016;28:78–88. 12. 14. Sailer ER, Subramanian LR, Rall B, et al. Acetyl-11-keto-_-boswellic acid (AKBA): structure requirements or binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 1996;117:615–618. doi: 10.1111/j.1476-5381.1996.tb15235.x 13. Kimmatkar N, Thawani V, Hingorani L, et al. Effi cacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003;10:3–7. doi: 10.1078/094471103321648593. 14. Gupta PK, Samarakoon SM, Chandola HM, et al. Clinical evaluation of Boswellia serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis) Ayu. 2011;32:478–482. doi: 10.4103/0974-8520.96119. 15. ebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Eff ects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39-46. 16. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO III, Harris CL, et al. The eff ect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum 2008;58:3183-91. 17. Rovetta G, Monteforte P, Molfetta G, Balestra V. Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions 2002;24(1):29-32. 18. Railhac JJ, Zaim M, Saurel AS, Vial J, Fournie B. Eff ect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double-blind, placebo-controlled pilot study using MRI. Clinical Rheumatology 2012;31(9):1347-57. 19. Pavelka K, Manopulo R, Busci L. Double-blind, dose-eff ect study of oral chondroitin 4 & 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica 1999;24:21-30. 20. Michel BA, Stucki G, Frey D, Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism 2005;52(3):779-86.
1.Dipanjan Guha, Arka Banerjee, Raktim Mukherjee, Biswaranjan Pradhan, Maria Peneva, Georgi Aleksandrov, Sujit Suklabaidya, Shantibhushan Senapati, Palok Aich, A probiotic formulation containing Lactobacillus bulgaricus DWT1 inhibits tumor growth by activating pro-inflammatory responses in macrophages, Journal of Functional Foods, Volume 56, 2019, Pages 232-245. 2. A . Merchak, S. Wachamo, L. Brown…; Lactobacillus from the Altered Schaedler Flora maintain IFNγ homeostasis to promote behavioral stress resilience; Brain, Behavior and Immunity 115 (2024) 458-469; 3. Scientific Opinion on the substantiation of health claims related to live yoghurt cultures and improved lactose digestion (ID 1143, 2976) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 https://www.efsa.europa.eu/en/efsajournal/pub/1763. 4. https://www.healthline.com/health-news/yogurt-may-help-reduce-depression . 5. R. Kanev, R. Nedeva; Development of professionally significant qualities for the maritime profession and their upgrading. The role of lifeguard training in building mental toughness and developing resilience in the conducted transoceanic sailing practice; Scientific and Practical Conference on Water Rescue; (IN PRINT). 6. R. Nedeva, S. Velikova, V. Stoyanov; Psychological assurance of ship crews: following the example of the Bulgarian Navy; X Jubilee International Congress of Psychology 2023 – Challenges to Modern Psychology; 7. R. Nedeva, D. Stavrev, B. Mednikarov, D. Doncheva, M. Georgieva, N. Vladimirova; The maritime profession and the physical and mental health of the crew: a study of anthropometrical and psychological alterations after the first transatlantic voyage to the Antarctic., Journal of IMAB - Annual Proceeding (Scientific Papers), Publisher: Peytchinski Publishing Ltd., ISSN: 1312 773X (Online), SUPPLEMENT, https://www.journal-imab-bg.org/issues-2023/Supplement/2023v29Supplement1Medicine.pdf. 8. N. Petrov, G. Alexandrov, M. Peneva; Newly found origin of probiotics in the Balkans; IPA World Congress, May 2014, Athens, Greece;. 9. M. Peneva, I. Misopoulos, E. Barzashka…; Application of probiotic formula, containing Lactobacillus bulgaricus DWT1, in patients with COVID-19; International Scientific Conference, Probiotics, Prebiotics, Gut Microbiota and Health; 2023, Bratislava, Slovakia. 10. D. Guha, A. Banerjee, R. Mukherjee…; A probiotic formulation, containing Lactobacillus bulgaricus DWT1, inhibits tumor growth by activating pro-inflammatory responses in macrophages; Journal of Functional Foods 56 (2019) 232-245